Drugs / WT1-Sensitized Allogeneic T-Lymphocytes
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT01640301 | Dec 2012 → Mar 2020 | MHC class I deficiency 2, childhood acute myeloid leukemia, disease related to hematopoietic stem cell transplant, therapy related acute myeloid leukemia and myelodysplastic syndrome | Fred Hutchinson Cancer Center | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | WT1-Sensitized Allogeneic T-Lymphocytes | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01640301 ↗ |
| Known as | TTCR-C4 | “inserted TCRC4 into Epstein-Bar virus-specific donor CD8+ T cells (TTCR-C4)” PMID 31235963 ↗ Jun 2019 |
| Route | Intravenous | “WT1-sensitized T cells intravenously (IV)” NCT01640301 ↗ |
| Target | WT1 | “Wilms tumor 1 (WT1)-specific T cell receptor” NCT01640301 ↗ |